Transdermal rotigotine: A new non-ergot dopamine agonist for the treatment of Parkinson's disease

Expert Opinion on Drug Delivery

Volumn 4, Issue 2, 2007, Pages 111-118

  Naidu, Y ^a   Chaudhuri, K Ray ^a,b,c  

^a UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Non ergot dopamine agonists; Parkinson's disease; Transdermal rotigotine

Indexed keywords

APOMORPHINE; CABERGOLINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUINPIROLE; ROPINIROLE; ROTIGOTINE;

APPLICATION SITE REACTION; BINDING AFFINITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED RELEASE FORMULATION; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG STRUCTURE; DRUG SUBSTITUTION; DYSKINESIA; FIBROSIS; HALLUCINATION; HUMAN; HYPOTENSION; LOCOMOTION; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PARKINSON DISEASE; REVIEW; SKIN MANIFESTATION; SOMNOLENCE; VALVULAR HEART DISEASE; VOMITING;

ADMINISTRATION, CUTANEOUS; ANIMALS; CLINICAL TRIALS; DOPAMINE AGONISTS; HUMANS; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 33847797214     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.2.111     Document Type: Review

References (36)

1. CLOUGH CG, CHAUDHURI KR, SETHI KD: Parkinson's disease. Health Press, Oxford (2003):7-19.
2. HOEHN MM, YAHR MD: Parkinsonism: onset, progression and mortality. Neurology (1967) 17:427-442.
3. CHAUDHURI KR, HEALY D, SCHAPlRA AHV: The non-motor symptoms of Parkinson's disease. Diagnosis and management. Lancet neurology (2006) 5:235-245.
4. OLANOW CW, WATTS RL, KOLLER WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology (2001) 56(5):S1-S88.
5. MARSDEN CD, PARKES JD: Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1:345-349.
6. RAJPUT AH, FENTON ME, BIRDI S et al.: Clinical-pathological study of levodopa complications. Mov. Disord. (2002) 17:289-296.
7. RASCOL O, GOETZ C, KOLLER W, SIMPATICO C: Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet (2002) 359:1589-1598.
8. OLANOW W, SCHAPIRA AH, RASCOL O: Continuous dopamine- receptor stimulation in early Parkinson's Disease. Trends Neurosci. (2000) 23:S117-126.
9. STOCCHI F, VACCA L, RUGGIERI S et al.: Intermittent vs. continuous levodopa administration in patients with advanced Parkinson's disease; a clinical and pharmacokinetic study. Arch. Neurol. (2005) 62:905-910.
10. DHAWAN V, HEALY D, PAL S, CHAUDHURI KR: The sleep related problems of Parkinson's disease. Age Ageing (2006) 35:220-228.
11. NYHOLM D, ASKMARK H, GOMES-TROLIN C et al.: Optimising Levodopa pharmacokinetics: Intestinal infusion versus oral sustained - release tablets. Clin. Neuropharmacol. (2003) 26(3):156-163.
12. MANSON AJ, TURNER K, LEES AJ: Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow up study of 64 patients. Mov. Disord. (2002) 17(6):1235-1241.
13. KATZENSCHLAGER R, HUGHES A, EVANS A et al.: Continuous subcutaneous apomorphine therapy improves dyskinesias in PD: a prospective study using single - dose challenges. Mov. Disord. (2005) 20:151-157.
14. OBESO JA, LUQUIN MR, MARTINEZ-LAGE JM: Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. Lancet (1986) 1:467-470.
15. KOLLER WC, HUTTON JT, TOLOSA E et al.: Immediate-release and controlled release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa study Group. Neurology (1999) 53:1012-1019.
16. RASCOL O:Transdermal delivery of dopaminergic agents. Neurology (2005) 65(1): S1-S2.
17. GROSSET KA, BONE I, GROSSET DG: Suboptimal medication adherence in Parkinson's disease. Mov. Disord. (2005) 20:1502-1507.
18. GROSSET D: The rotigotine transdermal patch may provide continuous dopaminergic stimulation in Early- stage Parkinson's disease. Adv. Clin. Neurol. Rehab. (2006) 6(2):32-34.
19. JENNER P: A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology (2005) 65(1) S3-S5.
20. HEINDL M, SCHELLER D, LEBSANFT K et al.: Continuous versus discontinuous administration of rotigotine in a rat model of dyskinesias. Parkinsonis and Related Disorders (2005) 11(2): PS002-PS006.
21. POEWE W, LUESSI F: Clinical studies with transdermal rotigotine in early Parkinson's Disease. Neurology (2005) 659(1): S11-S14.
22. ROTIGOTINE (NEUPRO) Summary of product characteristics. Schwarz Pharma.
23. PAUL ML, GRAYBIEL AM, DAVID JC et al.: D1-like and D2-1ike dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. Journal of Neuroscience (1992) 12:3729-3742.
24. HORVATH J, FROSS RD, KLEINER-FISMAN G et al.: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. (2004) 19:656-662.
25. HOROWSKI R, JAHNICHEN S, PERTZ HH: Fibrotic valvular heart disease is not related to chemical class but to biological function; 5-HT2B receptor activation plays crucial role. Mov. Disord. (2004) 19:1523-1524.
26. BARA-JIMENEZ W, BIBBIANI F, MORRIS MJ et al: Effects of serotonin 5-HT1A receptor agonist in advanced Parkinson's disease. Mov. Disord. (2005) 20:932-936.
27. TOMIYAMA M, KIMURA T, MAEDA T et al.: serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of PD. Neurosci. Res. (2005) 52:185-194.
28. SRINIVASAN J, SCHMIDT WJ: Treatment with alpha-2-adrenoceptor antagonists, 2 methoxy idazaoxan, protects 6-hydroxydopamine induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav. Brain Res. (2004) 154:353-363.
29. MUCKE HA: Rotigotine. Schwarz Pharma. Drugs (2003) 6:894-899.
30. THE PARKINSON STUDY GROUP: A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. (2003) 60:1721-1728.
31. WATTS RL, WENDT RL, NAUSIEDA B: Efficacy, safety and tolerability of the rotigotine patch in patients with early stage idiopathic Parkinson's Disease: multicentre, multinational, randomized, double blinded placebo controlled trial. Mov. Disord. (2004) 19(9): S258.
32. LEWITT PA, CHANG FL, Rotigotine transdermal system in treatment of patients with advanced stage Parkinson's disease. Eur. J. Neurol. (2005) 12(Suppl. 2):15 (SC 115) Abstract.
33. POEWE W, GILADI N, MAGUIRE D, BOROOJERDI B: Rotigotine transdermal patch in patients with Parkinson's Disease and motor fluctuations. 24h symptom control in a placebo- and pramipexole-controlled, randomized, doubleblind, double dummy trial Eur. J. Neurol. (2006) 13(Suppl. 2): 74(P1126)Abstract.
34. JANKOVIC JJ: Therapeutic strategies in Parkinson's disease. In: Parkinson's disease and movement disorders. Jankovic JJ, Tolosa E (Eds) Lippincott Williams & Wilkins, Philadelphia (2002): 116-151.
35. LEWITT PA, POEWE W, RASCOL O, GILADI N, PATTON J. Overnight switch from ropinirole, pramipexole and cabergoline to rotigotine transdermal patch. Eur. J. Neurol. (2006) 13(Suppl. 2):321 SATS-3.
36. STIASNY-KOLSTER K, KOHNEN R, SCHOLLMAYER E et al.: The Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov. Disord. (2004) 19:1432-1438.